Whitehawk Therapeutics Net Income Over Time
| WHWK Stock | 2.85 0.16 5.32% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Whitehawk Therapeutics Performance and Whitehawk Therapeutics Correlation. Whitehawk | Build AI portfolio with Whitehawk Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Whitehawk Therapeutics. Anticipated expansion of Whitehawk directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Whitehawk Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth 0.335 | Return On Assets | Return On Equity |
Investors evaluate Whitehawk Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Whitehawk Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Whitehawk Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Whitehawk Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Whitehawk Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Whitehawk Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Whitehawk Therapeutics and related stocks such as Clene Inc, MacroGenics, and Immix Biopharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLNN | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (277.3 K) | (16.2 M) | (19.3 M) | (9.7 M) | (29.9 M) | (49.5 M) | (39.4 M) | (35.5 M) | (33.7 M) |
| MGNX | 6.7 M | 6.7 M | 8.4 M | (260.8 K) | (38.3 M) | (20.1 M) | (58.5 M) | (19.6 M) | (171.5 M) | (151.8 M) | (117.8 M) | (190.9 M) | (120 M) | (9.1 M) | (67 M) | (60.3 M) | (63.3 M) |
| IMMX | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (1.1 M) | (24.4 M) | (8.2 M) | (15.4 M) | (21.6 M) | (19.5 M) | (18.5 M) |
| TVGN | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | 4.4 M | (60.5 M) | (10.1 M) | (9.1 M) | (9.6 M) |
| OVID | (447 K) | (447 K) | (447 K) | (447 K) | (447 K) | (13.2 M) | (22.4 M) | (64.8 M) | (52 M) | (59.3 M) | (80.7 M) | 122.8 M | (51.4 M) | (52.3 M) | (26.4 M) | (23.8 M) | (25 M) |
| ZNTL | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (45.7 M) | (117.8 M) | (158.7 M) | (236.8 M) | (292.2 M) | (165.8 M) | (149.3 M) | (156.7 M) |
| CNTX | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (24.6 M) | (7.5 M) | (7.5 M) | 6.6 M | (10.5 M) | (14.8 M) | (24 M) | (26.7 M) | (30.7 M) | (32.3 M) |
| ONCY | (574.5 K) | (29 M) | (36.4 M) | (23.5 M) | (18.6 M) | (13.7 M) | (15.1 M) | (15.6 M) | (17 M) | (45.6 M) | (16.8 M) | (21 M) | (19.1 M) | (20.6 M) | (31.7 M) | (28.5 M) | (27.1 M) |
| PLRX | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (30.3 M) | (631 K) | (39.7 M) | (17.9 M) | (123.3 M) | (161.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| ATOS | (122.9 K) | (3.4 M) | (5.1 M) | (10.8 M) | (14.7 M) | (15.8 M) | (6.4 M) | (8.1 M) | (11.4 M) | (17.2 M) | (17.8 M) | (20.6 M) | (26.2 M) | (30.1 M) | (25.5 M) | (23 M) | (21.8 M) |
Whitehawk Therapeutics and related stocks such as Clene Inc, MacroGenics, and Immix Biopharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Whitehawk Therapeutics financial statement analysis. It represents the amount of money remaining after all of Whitehawk Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Whitehawk Therapeutics | WHWK |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2 Headquarters Plaza, |
| Exchange | NASDAQ Exchange |
null 2.85
Check out Whitehawk Therapeutics Performance and Whitehawk Therapeutics Correlation. For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Whitehawk Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.